Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
MK-0812 is a potent and selective CCR2 antagonist, which was developed by Merck. This drug has entered clinical trials for both rheumatoid arthritis and multiple sclerosis. However, the rheumatoid arthritis trial was terminated because of lack of fav...